Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00549770 · ClinicalTrials.gov registry record · Phase 2

Efficacy and Safety of LCZ696A in Patients With Essential Hypertension

A Phase 2 study of Hypertension, sponsored by Novartis Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
1,334
Enrollment target
20
Study locations

NCT00549770 is a Phase 2 study of Hypertension that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,334 participants, below the 3,505-participant average among 470 other Hypertension trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00549770, a Phase 2 study of Hypertension, has completed, sponsored by Novartis Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
1,334 participants
Enrollment target
20
Study locations

Study Summary

This study was a dose-ranging efficiacy study in patients with essential hypertension to assess the blood pressure lowering effect, and safety of LCZ696 compared to valsartan and placebo. The study will also evaluate the efficacy and safety of AHU377 as compared to placebo.

Conditions Studied

Hypertension

Interventions

  • DRUG Placebo
  • DRUG Valsartan
  • DRUG LCZ696
  • DRUG AHU377

Study Locations (20)

California

  • Novartis Investigative Site - Buena Park
  • Novartis Investigative Site - Fair Oaks
  • Novartis Investigative Site - Long Beach
  • Novartis Investigative Site - Los Angeles
  • Novartis Investigative Site - Orangevale
  • Novartis Investigative Site - Santa Ana
  • Novartis Investigative Site - Stockton
  • Novartis Investigative Site - Tustin

Florida

  • Novartis Investigative Site - Jacksonville
  • Novartis Investigative Site - Pembroke Pines
  • Novartis Investigative Site - Pembroke Pines
  • Novartis Investigative Site - Pensacola

Illinois

  • Novartis Investigative Site - Chicago
  • Novartis Investigative Site - Chicago
  • Novartis Investigative Site - Peoria

Alabama

  • Novartis Investigative Site - Birmingham
  • Novartis Investigative Site - Muscle Shoals

Arizona

  • Novartis Investigative Site - Chandler

Georgia

  • Novartis Investigative Site - Augusta

Louisiana

  • Novartis Investigative Site - Baton Rouge

Trial Details

FieldValue
Enrollment Target 1,334 participants
Start Date 2007-09
Est. Completion 2008-07
Phase Phase 2

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00549770

The ClinicalTrials.gov registry entry for NCT00549770 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,334 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,505-participant average among 470 other Hypertension trials with a reported enrollment target (62% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT00549770 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT00549770 about?

NCT00549770 is a clinical study titled "Efficacy and Safety of LCZ696A in Patients With Essential Hypertension". This study was a dose-ranging efficiacy study in patients with essential hypertension to assess the blood pressure lowering effect, and safety of LCZ696 compared to valsartan and placebo. The study will also evaluate the efficacy and safety of AHU377 as compared to placebo.

What is the current status of trial NCT00549770?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,334 participants. The study started on 2007-09. Estimated completion is 2008-07.

What conditions does trial NCT00549770 study?

This clinical trial studies the following conditions: Hypertension.

What interventions are being tested in trial NCT00549770?

The interventions under investigation include: Placebo (DRUG), Valsartan (DRUG), LCZ696 (DRUG), AHU377 (DRUG).

Who is sponsoring clinical trial NCT00549770?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00549770 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hypertension

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.